-
3SBio Inc. Reports 16% YOY Revenue Growth in 2024 Interim Financial Report, Highlighting Biomedicine Segment Strength
•
3SBio Inc., a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1530), has reported its interim financial results for 2024. The company’s operating revenue for the period stood at RMB 4.389 billion (USD 614.6 million), reflecting a substantial year-on-year (YOY) increase of 16%. The adjusted EBITDA also…
-
Hangzhou Kang Ming’s ClouDr Posts Strong Financial Growth with Diversified Solutions and P2M Strategy
•
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the moniker “ClouDr” on the Hong Kong Stock Exchange (HKG: 9955), has reported its financial results for the first half of 2024, demonstrating a robust year-on-year (YOY) increase of 17.9%, with total revenues reaching RMB 2.125 billion (USD 298 million). The…
-
Everest Medicines Launches Trial for Personalized mRNA Cancer Vaccine EVM16 in Solid Tumors
•
Everest Medicines, a biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 1952), has announced the commencement of an investigator-initiated trial (ITT) for its cutting-edge personalized mRNA cancer vaccine, EVM16. The trial, spearheaded by Beijing Cancer Hospital and Fudan University Shanghai Cancer Center, is a…
-
Regeneron’s Linvoseltamab Faces FDA Complete Response Letter, Awaiting Reinspection of Manufacturer
•
Regeneron Pharmaceuticals Inc., a leading biopharmaceutical company based in the US and listed on the Nasdaq (NASDAQ: REGN), has encountered a setback in its pursuit of market approval for the bispecific antibody (BsAb) linvoseltamab. The US FDA has issued a Complete Response Letter (CRL) regarding the company’s filing for this…
-
Astellas Pharma Employee in China Formally Indicted on Espionage Suspicion
•
Astellas Pharma Inc., a Japanese pharmaceutical company listed on the Tokyo Stock Exchange (TYO: 4503), is facing a challenging situation as one of its employees, detained in China since March 2023 on suspicion of espionage, has reportedly been formally indicted by Chinese authorities. The news was reported by Reuters, citing…
-
CK Life Sciences’ Halneuron Receives FDA Fast-Track Designation for Chemotherapy-Induced Neuropathic Pain
•
CK Life Sciences (HKG: 0775), a biopharmaceutical company headquartered in China, has received fast-track designation from the US Food and Drug Administration (FDA) for its drug candidate Halneuron, which contains tetrodotoxin, for the treatment of chemotherapy-induced neuropathic pain (CINP). Halneuron is an innovative injectable form of tetrodotoxin, a naturally occurring…
-
GSC to Distribute Hecin’s Innovative PCR and RT-PCR Solutions in Middle Eastern Markets
•
Gulf Scientific Corporation (GSC), a prominent life sciences service provider headquartered in Dubai, United Arab Emirates, has announced a strategic collaboration with Guangdong Hecin Scientific Inc., a company based in China. As per the agreement, GSC is appointed as the exclusive agent for Hecin in the Middle East, covering key…
-
WuXi Biologics Reports Flat Revenues with Growth in Non-COVID-19 Projects in 2024H1 Financial Report
•
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) from China, has released its unaudited financial report for the first half of 2024. The company’s revenues for the period were on par with the same period in 2023, hitting RMB 8.57 billion (USD 1.2 billion), which…
